TheProfitWatch

AGEN - Agenus Inc.

Day 1m 10m 60m PreMarket Market AfterHours Gap
4.0 -0.02 (-0.62%) --- --- --- -0.03 (-0.75%) -0.02 (-0.38%) 0.0 (0.0%) -0.05 (-1.24%)

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: AfterHours

Earnings & Ratios

Basic EPS:
-1.0
Diluted EPS:
-1.0
Basic P/E:
-3.975
Diluted P/E:
-3.975
RSI(14) 1m:
71.43
VWAP:
3.98
RVol:
0.8437

Events

Period Kind Movement Occurred At
1m Price decrease 1m 3.89 -0.1 (-2.51%) Oct 15 09:37

Related News